Literature DB >> 23342240

Steps in the management of psoriatic arthritis: a guide for clinicians.

Raquel Cuchacovich1, Rodolfo Perez-Alamino, Ignacio Garcia-Valladares, Luis R Espinoza.   

Abstract

Psoriatic arthritis is a common systemic inflammatory disorder, which in addition to skin and nail involvement may be associated with peripheral and axial joint involvement, enthesitis, dactylitis, and important comorbidities - especially cardiovascular morbidity. Better insights into the involved pathogenic mechanisms have resulted in an improved therapeutic armamentarium, which targets key pathways in its pathogenesis. This has resulted in significant clinical responses to newer therapeutic agents, especially those directed at inhibition of tumor necrosis factor α. Biological therapy leads to significant levels of remission, improved quality of life, and retards or improves structural radiological damage.

Entities:  

Keywords:  T helper 17 cells; metabolic syndrome; psoriasis; psoriatic arthritis; rituximab; tumor necrosis factor α blockade

Year:  2012        PMID: 23342240      PMCID: PMC3539260          DOI: 10.1177/2040622312459673

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  59 in total

Review 1.  Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).

Authors:  Alexandra N Colebatch; Jonathan L Marks; Christopher J Edwards
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

2.  Psoriatic arthritis: radiographic joint repair following etanercept therapy.

Authors:  Ignacio Garcia-Valladares; Raquel Cuchacovich; Luis R Espinoza
Journal:  J Rheumatol       Date:  2012-01       Impact factor: 4.666

3.  Combination biologic treatment of refractory psoriasis and psoriatic arthritis.

Authors:  Raquel Cuchacovich; Ignacio Garcia-Valladares; Luis R Espinoza
Journal:  J Rheumatol       Date:  2012-01       Impact factor: 4.666

4.  HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype.

Authors:  Robert Winchester; Gregory Minevich; Valeria Steshenko; Brian Kirby; David Kane; David A Greenberg; Oliver FitzGerald
Journal:  Arthritis Rheum       Date:  2011-10-17

Review 5.  Genetics of susceptibility and treatment response in psoriatic arthritis.

Authors:  Darren D O'Rielly; Proton Rahman
Journal:  Nat Rev Rheumatol       Date:  2011-11-08       Impact factor: 20.543

6.  Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.

Authors:  George N Karanikolas; Eftyhia-Maria Koukli; Aikaterini Katsalira; Aikaterini Arida; Dimitrios Petrou; Eleni Komninou; Kalliopi Fragiadaki; Anna Zacharioudaki; Ioannis Lasithiotakis; Eirini Giavri; George Vaiopoulos; Petros P Sfikakis
Journal:  J Rheumatol       Date:  2011-09-01       Impact factor: 4.666

Review 7.  Psoriatic arthritis.

Authors:  Gleison Vieira Duarte; César Faillace; Jozélio Freire de Carvalho
Journal:  Best Pract Res Clin Rheumatol       Date:  2012-02       Impact factor: 4.098

8.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Authors:  Kim A Papp; Craig Leonardi; Alan Menter; Jean-Paul Ortonne; James G Krueger; Gregory Kricorian; Girish Aras; Juan Li; Chris B Russell; Elizabeth H Z Thompson; Scott Baumgartner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

Review 9.  Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy.

Authors:  H L Hébert; F R Ali; J Bowes; C E M Griffiths; A Barton; R B Warren
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

10.  Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

Authors:  Asta Baranauskaite; Helena Raffayová; N V Kungurov; Anna Kubanova; Algirdas Venalis; Laszlo Helmle; Shankar Srinivasan; Evgeny Nasonov; Nathan Vastesaeger
Journal:  Ann Rheum Dis       Date:  2011-10-12       Impact factor: 19.103

View more
  6 in total

Review 1.  Secukinumab: a promising therapeutic option in spondyloarthritis.

Authors:  Hernan Maldonado-Ficco; Rodolfo Perez-Alamino; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2016-07-20       Impact factor: 2.980

2.  Macrophage migration inhibitory factor (MIF) promoter polymorphisms (-794 CATT5-8 and -173 G>C): association with MIF and TNFα in psoriatic arthritis.

Authors:  Ramsés Morales-Zambrano; Luis A Bautista-Herrera; Ulises De la Cruz-Mosso; Guadalupe D Villanueva-Quintero; Jorge R Padilla-Gutiérrez; Yeminia Valle; Isela Parra-Rojas; Héctor Rangel-Villalobos; Sergio R Gutiérrez-Ureña; José F Muñoz-Valle
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies.

Authors:  Bernard Combe; Tsen-Fang Tsai; J Eugene Huffstutter; Aubrey Trevelin Sprabery; Chen-Yen Lin; So Young Park; Andris Kronbergs; Matthew M Hufford; Peter Nash
Journal:  Arthritis Res Ther       Date:  2021-01-27       Impact factor: 5.156

4.  Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination.

Authors:  Vibeke Strand; Philip J Mease; Ervant J Maksabedian Hernandez; Bradley S Stolshek; Lyrica X H Liu; David H Collier; Gregory Kricorian; Joseph F Merola
Journal:  RMD Open       Date:  2021-01

5.  Psoriatic arthritis among Egyptian patients with psoriasis attending the dermatology clinic: prevalence, comorbidities, and clinical predictors.

Authors:  Ayman El-Garf; Doaa Ahmed Teleb; Eman R Said; Mervat Eissa
Journal:  Reumatologia       Date:  2022-01-05

6.  Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry.

Authors:  Proton Rahman; Regan Arendse; Majed Khraishi; Dalton Sholter; Maqbool Sheriff; Emmanouil Rampakakis; Allen J Lehman; Francois Nantel
Journal:  BMJ Open       Date:  2020-08-13       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.